MX2022005594A - Lavados de salinidad elevada durante cromatografia de intercambio cationico para eliminar impurezas relacionadas con el producto. - Google Patents

Lavados de salinidad elevada durante cromatografia de intercambio cationico para eliminar impurezas relacionadas con el producto.

Info

Publication number
MX2022005594A
MX2022005594A MX2022005594A MX2022005594A MX2022005594A MX 2022005594 A MX2022005594 A MX 2022005594A MX 2022005594 A MX2022005594 A MX 2022005594A MX 2022005594 A MX2022005594 A MX 2022005594A MX 2022005594 A MX2022005594 A MX 2022005594A
Authority
MX
Mexico
Prior art keywords
cation exchange
product
exchange chromatography
high salinity
eliminate impurities
Prior art date
Application number
MX2022005594A
Other languages
English (en)
Spanish (es)
Inventor
Natalia Gomez
Malhar R Ambhaikar
Benjamin J Tillotson
Luis Diaz
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2022005594A publication Critical patent/MX2022005594A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Water Supply & Treatment (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2022005594A 2019-11-07 2020-11-04 Lavados de salinidad elevada durante cromatografia de intercambio cationico para eliminar impurezas relacionadas con el producto. MX2022005594A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962931874P 2019-11-07 2019-11-07
PCT/US2020/058774 WO2021091933A1 (en) 2019-11-07 2020-11-04 High salt washes during cation exchange chromatography to remove product-realated impurities

Publications (1)

Publication Number Publication Date
MX2022005594A true MX2022005594A (es) 2022-06-09

Family

ID=73598212

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005594A MX2022005594A (es) 2019-11-07 2020-11-04 Lavados de salinidad elevada durante cromatografia de intercambio cationico para eliminar impurezas relacionadas con el producto.

Country Status (14)

Country Link
US (1) US20220372071A1 (cg-RX-API-DMAC7.html)
EP (1) EP4055042A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022554283A (cg-RX-API-DMAC7.html)
KR (1) KR20220092958A (cg-RX-API-DMAC7.html)
CN (1) CN114651007A (cg-RX-API-DMAC7.html)
AR (1) AR120398A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020377919A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022008782A2 (cg-RX-API-DMAC7.html)
CA (1) CA3160208A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022001169A1 (cg-RX-API-DMAC7.html)
IL (1) IL292602A (cg-RX-API-DMAC7.html)
MX (1) MX2022005594A (cg-RX-API-DMAC7.html)
TW (1) TWI878377B (cg-RX-API-DMAC7.html)
WO (1) WO2021091933A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023007028A (es) * 2020-12-18 2023-09-21 Kiniksa Pharmaceuticals Ltd Composiciones de proteínas y métodos para producir y usar las mismas.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555661B1 (en) * 1997-08-25 2003-04-29 Anthony R. Torres Simple, environmentally benign, method for purifying protein A
HUE024877T2 (en) * 2007-10-30 2016-02-29 Genentech Inc Antibody purification by cation exchange chromatography
US20120282654A1 (en) * 2009-04-29 2012-11-08 Schering Corporation Antibody purification
US20120238730A1 (en) * 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
CN104628846B (zh) * 2013-11-06 2019-12-06 三生国健药业(上海)股份有限公司 重组蛋白质的纯化方法
WO2015198320A1 (en) * 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
PL3177643T3 (pl) * 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
EP3204415B1 (en) * 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
JP6699085B2 (ja) * 2015-03-25 2020-05-27 東ソー株式会社 Fc結合性タンパク質の精製方法
CA3026518A1 (en) * 2016-06-17 2017-12-21 Genentech, Inc. Purification of multispecific antibodies
JP2020525445A (ja) * 2017-06-21 2020-08-27 セファロン・インコーポレイテッドCephalon,Incorporated カチオン交換クロマトグラフィーの洗浄緩衝液
CN110305217B (zh) * 2018-03-27 2022-03-29 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用

Also Published As

Publication number Publication date
JP2022554283A (ja) 2022-12-28
JP2026048656A (ja) 2026-03-17
CL2022001169A1 (es) 2023-01-27
TWI878377B (zh) 2025-04-01
IL292602A (en) 2022-07-01
TW202523676A (zh) 2025-06-16
WO2021091933A1 (en) 2021-05-14
EP4055042A1 (en) 2022-09-14
AU2020377919A1 (en) 2022-06-16
US20220372071A1 (en) 2022-11-24
TW202132323A (zh) 2021-09-01
CL2024001792A1 (es) 2024-11-08
KR20220092958A (ko) 2022-07-04
CA3160208A1 (en) 2021-05-14
BR112022008782A2 (pt) 2022-07-26
AR120398A1 (es) 2022-02-09
CN114651007A (zh) 2022-06-21

Similar Documents

Publication Publication Date Title
EP4014502A4 (en) SCALING METHOD FOR ENCODER BLOCK
MY193158A (en) Continuous processes for the highly selective conversion of aldohexose-yielding carbohydrate to ethylene glycol
EP4410773A3 (en) Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid
ZA202109175B (en) Novel peptide compound or pharmaceutically acceptable salt thereof
MY198138A (en) Process For Pd-Catalyzed Hydroxycarbonylation Of Diisobutene: Ratio Of 3,5,5-Trimethylhexanoic Acid/H2O
MX373659B (es) Metodo para producir un pentapeptido sintetico.
BR112016013157A2 (pt) peptídeos resistentes à protease
IL281761A (en) Process of making calcium alpha-ketoglutarate
PL3823952T3 (pl) Oczyszczanie kwasu lewulinowego
PH12017502259A1 (en) Protease-resistant lipidated glp-1 analogs
CL2022001169A1 (es) Lavados de salinidad elevada durante cromatografía de intercambio catiónico para eliminar impurezas relacionadas con el producto
SG11202007168TA (en) Industrial process for continuously synthesizing alkane-sulphonic acid
MX2021006692A (es) Proceso mejorado para preparar ozanimod.
SG11202102015QA (en) Fused ring derivative used as fgfr4 inhibitor
SG11202101575TA (en) Process for the production of high purity isobutylene
MX381459B (es) Metodo de manufactura de proteina.
MX2017012027A (es) Desaminacion de nucleosidos organofosforados.
MX376203B (es) Un proceso novedoso para la sintesis de 1-aril-1-trifluoro-metil-ciclopropanos.
MX2019005785A (es) Proceso para la purificacion de 1-(4-clorofenil)pirazol-3-ol.
WO2016202808A3 (en) NEW SYNTHESIS OF TAPENTADOL-HCl INTERMEDIATES
MX2020010343A (es) Proceso para la purificacion de biocomposiciones complejas.
PT4263568T (pt) Métodos para a purificação de proteína de fusão fc-péptido reenrolada
MY194343A (en) Drilling tender unit
IT201900025186A1 (it) Metodo per la purificazione di cisteammina
CL2022001168A1 (es) Acondicionamiento de la carga con salinidad elevada durante la cromatografía de intercambio catiónico para eliminar impurezas relacionadas del producto